Our pipeline of medicines is deep and diverse. We are a development house, focused on pipeline investments to continue moving up the value chain. We aim to develop more complex and novel products, providing greater opportunities to target gaps in patient care where others may not focus. We do this through a first-to-market emphasis and serving a key-pillar in our mission of expanding patient access. This means actively looking into opportunities to build a critical mass of new drugs submitted through the 505(b)(2) regulatory pathway and New Chemical Entities (NCEs). We also invest in life-cycle management of certain key products in our current portfolio, with a focus on making improvements to existing products and expanding formulations to make them more widely available to those who may not have previously had access.